Open access
Aug 2026
A modified cyclosporine enhances lentivector transduction ex vivo and in vivo by degrading IFITM3.
BG147 promises to transform ex vivo and in vivo gene therapies by transiently inhibiting intrinsic immune barriers mediated by IFITM3 to enhance a wide range of protocols.
Dara Annett, Bethan J. Critchley, Kate L. Morling et al.
· Molecular Therapy · 0 citations